PL374510A1 - Podstawione benzopirany jako selektywni agoniści estrogenowego receptora beta - Google Patents

Podstawione benzopirany jako selektywni agoniści estrogenowego receptora beta

Info

Publication number
PL374510A1
PL374510A1 PL02374510A PL37451002A PL374510A1 PL 374510 A1 PL374510 A1 PL 374510A1 PL 02374510 A PL02374510 A PL 02374510A PL 37451002 A PL37451002 A PL 37451002A PL 374510 A1 PL374510 A1 PL 374510A1
Authority
PL
Poland
Prior art keywords
estrogen receptor
selective estrogen
beta agonists
agonists
substituted benzopyrans
Prior art date
Application number
PL02374510A
Other languages
English (en)
Other versions
PL205733B1 (pl
Inventor
Jeffrey Alan Dodge
Venkatesh Gary Krishnan
Charles Willis Lugar Iii
Blake Lee Neubauer
Bryan Hurst Norman
Lance Allen Pfeifer
Timothy Ivo Richardson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL374510A1 publication Critical patent/PL374510A1/pl
Publication of PL205733B1 publication Critical patent/PL205733B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
PL374510A 2001-11-19 2002-11-07 Podstawiona pochodna benzopiranu, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie PL205733B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11

Publications (2)

Publication Number Publication Date
PL374510A1 true PL374510A1 (pl) 2005-10-31
PL205733B1 PL205733B1 (pl) 2010-05-31

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374510A PL205733B1 (pl) 2001-11-19 2002-11-07 Podstawiona pochodna benzopiranu, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie

Country Status (23)

Country Link
US (1) US7217734B2 (pl)
EP (1) EP1448544B1 (pl)
JP (1) JP4381810B2 (pl)
KR (1) KR100950616B1 (pl)
CN (1) CN1312147C (pl)
AT (1) ATE362471T1 (pl)
AU (1) AU2002359283B2 (pl)
CA (1) CA2467013C (pl)
CY (1) CY1106726T1 (pl)
DE (1) DE60220179T2 (pl)
DK (1) DK1448544T3 (pl)
EA (1) EA007382B1 (pl)
EC (1) ECSP045113A (pl)
ES (1) ES2286322T3 (pl)
HR (1) HRP20040439A2 (pl)
HU (1) HU229351B1 (pl)
IL (3) IL161325A0 (pl)
MX (1) MXPA04004703A (pl)
NO (1) NO328563B1 (pl)
NZ (1) NZ531850A (pl)
PL (1) PL205733B1 (pl)
PT (1) PT1448544E (pl)
WO (1) WO2003044006A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406373T1 (de) * 2003-04-21 2008-09-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
DE602004025460D1 (de) 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CN101052641A (zh) 2004-09-07 2007-10-10 惠氏公司 6H－[1]苯并吡喃并[4,3－b]喹啉及其作为雌激素药物的用途
CA2578300A1 (en) * 2004-10-18 2006-04-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
CA2587669A1 (en) * 2004-11-18 2006-05-26 Janssen Pharmaceutica N.V. Novel 2h-chromene derivatives as selective estrogen receptor modulators
WO2006088716A1 (en) * 2005-02-15 2006-08-24 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US9974776B2 (en) 2013-12-05 2018-05-22 Karo Pharma Ab Estrogen receptor beta agonists for use in treating mesothelioma
CN108884124A (zh) 2015-09-17 2018-11-23 俄亥俄州创新基金会 碳硼烷化合物及其使用方法
WO2021183760A1 (en) * 2020-03-11 2021-09-16 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erβ) agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
KR100263137B1 (ko) 1995-09-08 2000-08-01 오테스코그 페르 오판 수용체
AU8102398A (en) * 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2002542187A (ja) 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
IL150463A0 (en) 1999-12-30 2002-12-01 Signal Pharm Inc Compounds and methods for modulation of estrogen receptors
AU2001256164A1 (en) * 2000-03-01 2001-09-12 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
JP2003528858A (ja) 2000-03-27 2003-09-30 アクゾ・ノベル・エヌ・ベー エストロゲン関連治療用のノンステロイド系四環式化合物
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6914074B2 (en) 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
MXPA04004703A (es) 2004-08-19
NO20042583L (no) 2004-06-18
DK1448544T3 (da) 2007-10-08
ATE362471T1 (de) 2007-06-15
IL185867A (en) 2009-09-22
IL185867A0 (en) 2008-01-06
AU2002359283B8 (en) 2003-06-10
ES2286322T3 (es) 2007-12-01
CY1106726T1 (el) 2012-05-23
WO2003044006A1 (en) 2003-05-30
JP2005513027A (ja) 2005-05-12
CA2467013C (en) 2010-08-10
CN1589268A (zh) 2005-03-02
EA200400695A1 (ru) 2004-12-30
EA007382B1 (ru) 2006-10-27
HUP0402628A2 (hu) 2005-04-28
CA2467013A1 (en) 2003-05-30
DE60220179T2 (de) 2008-02-07
IL161325A (en) 2008-07-08
KR100950616B1 (ko) 2010-04-01
JP4381810B2 (ja) 2009-12-09
HRP20040439A2 (en) 2005-04-30
IL161325A0 (en) 2004-09-27
CN1312147C (zh) 2007-04-25
PT1448544E (pt) 2007-08-10
KR20040063963A (ko) 2004-07-15
NZ531850A (en) 2007-01-26
AU2002359283B2 (en) 2007-06-21
ECSP045113A (es) 2004-07-23
PL205733B1 (pl) 2010-05-31
NO328563B1 (no) 2010-03-22
DE60220179D1 (de) 2007-06-28
AU2002359283A1 (en) 2003-06-10
EP1448544B1 (en) 2007-05-16
US7217734B2 (en) 2007-05-15
HU229351B1 (en) 2013-11-28
EP1448544A1 (en) 2004-08-25
HK1068349A1 (en) 2005-04-29
US20040249167A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
IL185867A0 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
ATE457308T1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CY1110443T1 (el) Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
PT925301E (pt) Derivados altamente lipofilos de camptotecina
NZ511593A (en) Substituted benzopyran analogs for the treatment of inflammation
MY141733A (en) Benzimidazole and pyridylimidazole derivatives as ligands for gabaa receptors
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
WO2003024935A3 (en) Substituted pyrazolyl compounds for the treatment of inflammation
WO2003027075A3 (en) Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
PL371127A1 (pl) Pochodne 6-amino-morfinianu, metody ich otrzymywania oraz ich zastosowania
EP1453812A4 (en) CYTOTOXIC AGENTS
PL376896A1 (pl) Sposoby wytwarzania 5-androstenów podstawionych w pozycji C-7
BR0214918A (pt) 6h-dibenzo[c,h]cromenos substituìdos como agentes estrogênicos
MY117975A (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
HUP0402283A3 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine, process for their preparation and pharmaceutical compositions containing them
MXPA03003466A (es) Derivados de piranosido.
ES2103237A1 (es) Nuevo compuesto derivado del cromeno
SI1453820T1 (en) Substituted 6h-dibenzo(c,h)chromenes as estrogenic agents
HN2001000165A (es) Derivados de imidazol

Legal Events

Date Code Title Description
RECP Rectifications of patent specification